Product Name:  Phenylbutazone Paste, 12 gm

Description: 

Indications: For the relief of inflammatory conditions associated with the musculoskeletal system in horses.

Pharmacology: Phenylbutazone is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties.
Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones.

Dosage and Administration: Administer 1 to 2 g of phenylbutazone per 500 lbs. of body weight, but not to exceed 4 g daily. Oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.
Guidelines to Successful Therapy:
1. Use a relatively high dose for the first 48 hours, then reduce gradually to maintenance dose. Maintain the lowest dose capable of producing the desired clinical response.
2. Response to PHENYLBUTAZONE therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after five (5) days, re-evaluate the diagnosis and the therapeutic approach.
3. When administering PHENYLBUTAZONE, the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose.
4. Many chronic conditions will respond to PHENYLBUTAZONE therapy, but discontinuance of treatment may result in recurrence of symptoms.

Contraindication(s): Use with caution in patients who have a history of drug allergy.

Caution(s): Keep out of the reach of children.
Stop medication at the first sign of gastro-intestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man. Fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two (2) weeks thereafter. Any significant fall in the total white count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of appropriate counter measures.
In the treatment of inflammatory conditions associated with infectious, specific anti-infective therapy is required.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Warning(s): Not for use in horses intended for food.

Presentation: 60 g syringes.